Pharmaceutical Technology22h agobearish
Pfizer repels Covid-19 sales tumble to raise 2026 guidanceFuelled by blockbusters such as Eliquis, Pfizer is cementing its post-Covid revenue legacy.
News
High-signal headlines only - macro events, earnings, M&A, regulatory. Listicles and analyst clickbait filtered out by default. Refreshed hourly.
490last 24h
2474last 7d
479● bullish (7d)
251● bearish (7d)
197publishers
BioPharma Dive5d agobearish
Alnylam plunges as earnings deliver ‘one-two punch’The RNA-focused biotech shed 30% of its market value — or close to $12 billion — amid growing investor concerns about its main drug business.
Zacks12d agobearish
Biogen Q2 Earnings: Can New Drugs Counter Falling MS Sales?BIIB heads into Q2 results with new launches expected to offset weaker MS drug sales as investors watch Leqembi trends and the Apellis deal impact.
Stocktwits47d agobearish
PFE Stock Drops 3% On Surprise CFO Exit Despite Reaffirmed 2026 GuidanceIn a filing with the Securities and Exchange Commission, Pfizer said Executive Vice President and Chief Financial Officer Dave Denton notified the company on June 16 that he will step down effective August 15.
MT Newswires91d agobearish
Top Midday Stories: PayPal Q2 EPS Guide Undershoots Expectations, Plans 20% Workforce Cut; Palantir Shares Fall Despite Strong Earnings, GuidanceAll three major US stock indexes were up in late-morning trading Tuesday, as oil prices slid despite